C4 Therapeutics, Inc.

Colorectal cancer (CRC) is the second deadliest cancer in the United States, according to the American Cancer Society, and impacts both men and women. Current treatment options, including FDA-approved BRAF inhibitors, can lead to resistance with median progression-free survival rates of less than 15 months across CRC and other malignancies with a BRAF mutation.     Our CFT1946 program targets colorectal cancers with BRAF V600 mutations by completely removing the abnormal BRAF protein rather than inhibiting it, potentially leading to better outcomes by overcoming resistance.   Learn more about our program at https://bit.ly/43ygxPi, and find out how to detect and diagnose CRC early at https://bit.ly/4i8hdmx.  #ColorectalCancerAwarenessMonth #colorectalcancer #CRC #cancerresearch #TPD

March is Multiple Myeloma Awareness Month, an opportunity to raise awareness of multiple myeloma – a blood cancer that is difficult to diagnose because it often causes no symptoms before reaching an advanced stage. Some early signs of myeloma include bone pain or weakness, infections or low blood counts. Our cemsidomide program is designed to target IKZF1/3 transcription factors that drive multiple myeloma. Learn more on our website: https://bit.ly/4bsj5TU #myelomaawarenessmonth #multiplemyeloma #myeloma #bloodcancer

C4T leadership will participate in the Leerink Partners Global Healthcare Conference on March 10 in Miami, Florida. #biotech

On International Women’s Day we celebrate the women who drive life-changing progress within biotech, including our own teammates who are pioneering a new generation of #TPD medicines. We thank our colleagues for their dedication to advancing our mission and inspiring each other and others to use their passion for science to reach new heights.   Paige Mahaney, our chief scientific officer, is part of the majority-women executive leadership team at C4T who use their position and experience to encourage younger generations to pursue careers in #STEM. #IWD2025

Happy Employee Appreciation Day to our #C4TxTeam, a group of catalysts who join together each day with a shared motivation to deliver transformative medicines to patients. We’re proud of each member of our team for the role they have played to get us this far - reaching ten years as a company this year. We thank them for bringing their unique selves to work every day and supporting each other to help us accomplish great things. To celebrate our teammates we all received a sweet treat – C4T M&Ms that hold a striking resemblance to our logo! #EmployeeAppreciationDay #biotech

We announced fourth quarter and full-year 2024 financial results and recent business highlights. Read more about our progress: https://bit.ly/41c5wEm

We welcomed students from the Ewha Womans University in Korea through its “Pharm Challenger Project” – an opportunity for students to visit organizations researching new areas of medicine. For their project, these women are eagerly exploring the world of targeted protein degradation, researching the current state of the field and its potential to impact patients. Our team had a fantastic day with the students, guiding them through our #TPD approach and mission to create a new way to treat diseases like cancer. As we celebrate International Day of Women and Girls in Science, hear from our vice president of clinical pharmacology, Eunju Hurh, about the impact of helping young scientists learn more about the many different areas of therapeutic development. #February11 #WomenInScience #IDWGS

Transforming a patient’s treatment experience is one of the driving factors of our work to create a new generation of #TPD medicines. Treatment resistance is a defining challenge in our disease areas of focus, including multiple myeloma and BRAF V600 mutant cancers. Learn about our approach to treating cancer by degrading disease-causing proteins to potentially prevent new mutations that cause treatment resistance. https://bit.ly/3Q1804k #WorldCancerDay #cancerresearch #cancer #myeloma #lymphoma #CRC #melanoma

Have you visited our Scientific Presentations & Publications page? Check it out to view past presentations from industry events and learn about progress across our discovery platform and clinical programs: https://bit.ly/405hAYS #TPD #biotech

Learn about cancers with BRAF mutations – the target of our CFT1946 program, an orally bioavailable BiDAC™ degrader of BRAF V600 mutations. CFT1946 is currently being studied in a Phase 1/2 clinical trial in patients with BRAF V600 mutant solid tumors. BRAF V600 mutations are found in cancers including melanoma and colorectal cancer (CRC). Visit our website for more: https://bit.ly/43ygxPi